Cancer Research and Treatment

Original Article

Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients: Min Ae Cho, Soo Young Jeong, Insuk Sohn, Myeong-Seon Kim, Jun Hyeok Kang, E Sun Paik, Yoo-Young Lee, Chel Hun Choi; Cancer Res Treat. 2020;52(2):645-654. Published online January 16, 2020; DOI: https://doi.org/10.4143/crt.2019.509

Abstract PDF Supplementary Material PubReader ePub

Purpose
We investigated the impact of four types of antihypertensive medications, angiotensin receptor blockers (ARBs), beta blockers (BBs; both selective and non-selective), calcium channel blockers (CCBs), and thiazide diuretics (TDs) on survival outcomes in epithelial ovarian cancer (EOC).
Materials and Methods
A single-institutional retrospective chart review of 878 patients with EOC was performed. Survival was compared according to use of the four antihypertensive medications during primary treatment. Propensity score matching (ratio 1:3) was performed to control possible associated covariates, such as age, International Federation of Gynecology and Obstetrics stage, residual status after primary debulking surgery, and co-morbidity.
Results
Among 878 patients, 56 patients (6.4%) were ARB users, 62 (7.1%) were BB users, 107 (12.2%) were CCBs users and 32 (3.6%) used TDs. Median progression-free survival (PFS) for ARB, BB, and CCB users was 37.8, 27.2, and 23.6 months compared with 33.6 months for non-users. ARB was associated with 35% decreased risk of disease progression (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.42 to 0.99; p=0.046) in multivariate analysis. After propensity score matching, median PFS for ARB users was 37.8 months and ARB use remained to be associated with lower recurrence rate in univariate (p=0.035) and multivariate analysis (HR, 0.60; 95% CI, 0.39 to 0.93; p=0.022).
Conclusion
In this study, ARBs use during primary treatment is associated with lower recurrence in EOC patients. However, CCBs, BBs, and TDs did not show beneficial impact.

Citations

Citations to this article as recorded by

Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence
Pian Wang, Xinmiao Zhang, Jinhai Shen
Expert Review of Anticancer Therapy.2025; 25(3): 241. CrossRef
Ramipril, perindopril and trandolapril as potential chemosensitizers in ovarian cancer: Considerations for drug repurposing
Katarzyna Regulska, Paulina Gieremek, Marcin Michalak, Tomasz Kolenda, Marlena Janiczek-Polewska, Joanna Kozłowska-Masłoń, Zefiryn Cybulski, Beata J. Stanisz
Drug Discovery Today.2025; 30(4): 104331. CrossRef
Genetically proxied therapeutic effect of antihypertensive drug use, breast cancer, and ovarian cancer’s risk: a drug-target Mendelian randomization study
Chunxiao Dang, Ruohan Wang, Yunzhen Shi, Pengfei Liu, Xiaofeng Wang, Jinxing Liu, Xiao Yu, Dongxu Jin, Qing Ma
BMC Cancer.2025;[Epub] CrossRef
The Potential Impact of Renin–Angiotensin System Inhibitors on Cancer Survival and Recurrence: A Systemic Review and Meta-Analysis
Kaneez Fatima, Aayat Ellahi, Mariam Adil, Haider Kashif, Muhammad Uzair, Naela Ashraf, Mehak Barolia, Mujtaba Hyder, Areeba Nakhuda, Michelle Ayub, Sofia Jamil Butt, Ahmed Mustafa Rashid
Journal of Cardiovascular Pharmacology.2025; 85(1): 35. CrossRef
The Impact of Beta Blockers on Survival in Cancer Patients: A Systematic Review and Meta-Analysis
Alisha E. Sharma, Stephanie Chan, Adam S. Komorowski, Xingshan Cao, Yizhuo Gao, Kushal Kshatri, Kairavi Desai, Markus Kuksis, Michael Rosen, Anjali Sachdeva, Isabella Kojundzic, Saif Samari, Iacovos P. Michael, Husam Abdel-Qadir, Katarzyna J. Jerzak
Cancers.2025; 17(8): 1357. CrossRef
Impact of beta blockers on cancer neuroimmunology: a systematic review and meta-analysis of survival outcomes and immune modulation
Fangyuan Zhang, Yu Wang, Feng Liu, Yixian Li, Xinxin Liu, Xueying Ren, Xi Yuan
Frontiers in Immunology.2025;[Epub] CrossRef
In Vivo Antihypertensive and Ex Vivo Vasodilatory Studies of Taxifolin
Xuye Wang, Xiangyang Xu, Wan Yin Tew, Liyun Ouyang, Xiaoning Yang, Hui Wei Loh, Wen Xu, Wei Xu, Mun Fei Yam
Pharmaceuticals.2025; 18(9): 1420. CrossRef
Effectiveness and Safety of Common Non-Oncologic Pharmaceuticals in Cancer Management: A Systematic Review
Luc ZONGO, Théodora M. ZOHONCON, Bakary Tientigui DEMBELE, Heiko LANGE, Rosemary R. CANFUA, Davy P-W BEMBAMBA, Yilédoma T. M. LENGANE, Wilfried F. P. TRAORE, Lucien KABORE, Michel PALUKU MUKULULI, Raogo OUEDRAOGO, Mimtiri S. ZONGO, Esther Hor
Journal of Drug Delivery and Therapeutics.2025; 15(10): 304. CrossRef
Evaluation of antihypertensive medications use and survival in patients with ovarian cancer: a population-based retrospective cohort study
Rūta Everatt, Irena Kuzmickienė, Birutė Brasiūnienė, Ieva Vincerževskienė, Birutė Intaitė, Saulius Cicėnas, Ingrida Lisauskienė
BMC Women's Health.2024;[Epub] CrossRef
Advanced progress of the relationship between renin–angiotensin–aldosterone system inhibitors and cancers
Ruixing Zhang, Hongtao Yin, Mengdi Yang, Jinjin Liu, Donghu Zhen, Zheng Zhang
Journal of Hypertension.2024; 42(11): 1862. CrossRef
Impact of ACEI/ARB use on the survival of hypertensive patients with cancer: A meta‑analysis
Yao Xiao, Xinlong Chen, Wancheng Li, Xin Li, Wence Zhou
Oncology Letters.2024;[Epub] CrossRef
Renin-Angiotensin-Aldosterone System Inhibitors and Development of Gynecologic Cancers: A 23 Million Individual Population-Based Study
Nhi Thi Hong Nguyen, Phung-Anh Nguyen, Chih-Wei Huang, Ching-Huan Wang, Ming-Chin Lin, Min-Huei Hsu, Hoang Bui Bao, Shuo-Chen Chien, Hsuan-Chia Yang
International Journal of Molecular Sciences.2023; 24(4): 3814. CrossRef
Association of Hypertension and Breast Cancer: Antihypertensive Drugs as an Effective Adjunctive in Breast Cancer Therapy
Yuanyuan Fan, Nazeer Hussain Khan, Muhammad Farhan Ali Khan, MD Faysal Ahammad, Tayyaba Zulfiqar, Razia Virk, Enshe Jiang
Cancer Management and Research.2022; Volume 14: 1323. CrossRef
The effect of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on progression of gastric cancer: systematic review and meta-analysis
Seyed Ali Mehrdad, Farshad Mirzavi, Seyed Mohammad Reza Seyedi, Ahmad Asoodeh
Anti-Cancer Drugs.2022; 33(10): 983. CrossRef
Repurposing approved drugs for cancer therapy
Catherine H Schein
British Medical Bulletin.2021; 137(1): 13. CrossRef
Norepinephrine inhibits migration and invasion of human glioblastoma cell cultures possibly via MMP-11 inhibition
Jing Zhong, Weiran Shan, Zhiyi Zuo
Brain Research.2021; 1756: 147280. CrossRef
Antihypertensive Drug Use and the Risk of Ovarian Cancer Death among Finnish Ovarian Cancer Patients—A Nationwide Cohort Study
Eerik E. E. Santala, Miia Artama, Eero Pukkala, Kala Visvanathan, Synnöve Staff, Teemu J. Murtola
Cancers.2021; 13(9): 2087. CrossRef
The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer
José A. Carlos-Escalante, Marcela de Jesús-Sánchez, Alejandro Rivas-Castro, Pavel S. Pichardo-Rojas, Claudia Arce, Talia Wegman-Ostrosky
Frontiers in Oncology.2021;[Epub] CrossRef
Post-Diagnostic Beta Blocker Use and Prognosis of Ovarian Cancer: A Systematic Review and Meta-Analysis of 11 Cohort Studies With 20,274 Patients
Zhao-Yan Wen, Song Gao, Ting-Ting Gong, Yu-Ting Jiang, Jia-Yu Zhang, Yu-Hong Zhao, Qi-Jun Wu
Frontiers in Oncology.2021;[Epub] CrossRef
Stress Hormones: Emerging Targets in Gynecological Cancers
Guoqiang Chen, Lei Qiu, Jinghai Gao, Jing Wang, Jianhong Dang, Lingling Li, Zhijun Jin, Xiaojun Liu
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
The Effect of Local Renin Angiotensin System in the Common Types of Cancer
Moudhi Almutlaq, Abir Abdullah Alamro, Hassan S. Alamri, Amani Ahmed Alghamdi, Tlili Barhoumi
Frontiers in Endocrinology.2021;[Epub] CrossRef
Does sympathetic nervous system modulate tumor progression? A narrative review of the literature
Ioannis Stavropoulos, Angelos Sarantopoulos, Anastasios Liverezas
Journal of Drug Assessment.2020; 9(1): 106. CrossRef

16,548 View
165 Download
23 Web of Science
22 Crossref

First
Prev
Page of 1
Next
Last

Search